Peer-reviewed veterinary case report
Monocyte and lymphocyte counts predict relapse in dogs with lymphoma
By Sara Cermeno et al.·Published in Animals·2025·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Monocyte and Lymphocyte Count, and Lymphocyte/Monocyte Ratio as Prognostic Factors at the Time of First Relapse in Canine Diffuse Large B-Cell Lymphoma Patients Receiving Chemotherapy
- Species:
- dog
Plain-English summary
A group of dogs with diffuse large B-cell lymphoma (a type of cancer) undergoing chemotherapy were studied to see if certain blood cell counts could predict their survival after the first relapse. Researchers looked at the levels of monocytes and lymphocytes, as well as the ratio between them, but found that these factors did not significantly predict how long the dogs would live after treatment. However, they suggested that keeping an eye on lymphocyte counts during chemotherapy might help veterinarians spot any disease progression. More research is needed to confirm these findings and improve treatment strategies.
People also search for: dog lymphoma treatment · canine cancer survival rates · lymphocyte count in dogs
Abstract
Simple Summary Canine lymphomas account for the majority of haematopoietic tumours in veterinary clinical practice. Several prognostic factors have been evaluated in dogs with diffuse large B-cell lymphoma (DLBCL) and, more recently, the role of leukocytes has been of increased interest. The main objective of this study was to assess the prognostic value of absolute monocyte and lymphocyte count, as well as lymphocyte-to-monocyte ratio (LMR), at the time of first relapse in a population of dogs with diffuse large B-cell lymphoma treated with CEOP-based chemotherapy. Additionally, absolute monocyte and lymphocyte count, as well as LMR, were evaluated for their prognostic value at the time of diagnosis and throughout different timepoints during the course of the chemotherapy treatment. Monocyte counts, lymphocyte counts, and their ratio were not found to be significant predictors of overall survival at relapse or at the time of diagnosis in this population of dogs. Furthermore, our findings suggest that monitoring of the absolute lymphocyte count throughout chemotherapy treatment and during follow-up in these dogs may be of clinical help to identify disease progression. Larger, controlled prospective studies evaluating blood cell counts throughout the course of chemotherapy and at relapse are needed to evaluate these findings further.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/41514696